CompletedPhase 3

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

United States58 participantsStarted 2017-01-11

Plain-language summary

The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent and adult participants with aHUS who had not previously used a complement inhibitor.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female ≥ 12 years of age and weighing ≥ 40 kg at the time of consent.
✓. Evidence of thrombotic microangiopathy, including low platelet count, hemolysis (breaking of red blood cells inside of blood vessels), and decreased kidney function.
✓. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study drug. Participants who received a meningococcal vaccine less than 2 weeks before initiating ravulizumab treatment must have received treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Participants who had not been vaccinated prior to initiating ravulizumab treatment should have received prophylactic antibiotics prior to and for at least 2 weeks after meningococcal vaccination. Participants \< 18 years of age must have been vaccinated against haemophilus influenzae type b and streptococcus pneumoniae according to national and local vaccination schedule guidelines.
✓. Female participants of childbearing potential and male participants with female partners of childbearing potential had to use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ravulizumab.

Exclusion criteria

✕. A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 deficiency (activity \< 5%).
✕. Shiga toxin-related hemolytic uremic syndrome.
✕. Positive direct Coombs test.
✕. Pregnancy or breastfeeding.
✕. Identified drug exposure-related hemolytic uremic syndrome (HUS).
✕. Bone marrow transplant/hematopoietic stem cell transplant within last 6 months prior to start of Screening.
✕. HUS related to known genetic defects of cobalamin C metabolism.
✕. Systemic sclerosis (scleroderma), systemic lupus erythematosus, or antiphospholipid antibody positivity or syndrome.

What they're measuring

Percentage Of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26

Timeframe: Week 26

Trial details

NCT IDNCT02949128

SponsorAlexion Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-01-24

Results submitted2019-12-11

View on ClinicalTrials.gov More Atypical Hemolytic Uremic Syndrome (aHUS) trials